TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-200-A0201 Targeting HPV16 to Treat Solid Tumors

TSC-200-A0201 is TScan’s third cleared IND for the T-Plex solid tumor program supporting the use of multiple TCRs in combination to deliver customized, multiplexed TCR-T cell therapies based on... | June 6, 2023

Related Keywords

Debora Barton ,Heather Savelle ,Gavin Macbeath ,Joyce Allaire ,Company Immunobank ,Nasdaq ,Drug Administration ,Globe Newswire Tscan Therapeutics Inc ,Securities Exchange ,Lifesci Advisors ,Tscan Therapeutics Inc ,Chief Medical ,Chief Executive Officer ,Private Securities Litigation Reform Act ,Securities Exchange Act ,Financial Condition ,Annual Report ,Sci Advisors ,Tscan Therapeutics ,Nc Stock Exchange ,News ,Information ,Press Release ,Us ,Third ,Leared ,End ,Or ,The ,Olid ,Humor ,Program ,Supporting ,Tse ,F ,Multiple ,Crs ,N ,Combination ,O ,Eliver ,Multiplexed ,Fell ,Therapies ,Ased Tcrx Us89854m1018 ,